Tectonic Therapeutic, Inc.(TECX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TECX Tectonic Therapeutic, Inc.

Market Closed 01-23 16:00:00 EST

20.16

+1.11

+5.83%

盘后20.47

+0.31+1.55%

17:57 EST

High20.66	Low18.78	Vol279.68K
Open19.04	D1 Closing19.05	Amplitude9.88%
Mkt Cap377.32M	Tradable Cap196.40M	Total Shares18.72M
T/O5.62M	T/O Rate2.87%	Tradable Shares9.74M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TECX","market":"US","secType":"STK","nameCN":"Tectonic Therapeutic, Inc.","latestPrice":20.16,"timestamp":1769202000000,"preClose":19.05,"halted":0,"volume":279684,"hourTrading":{"tag":"盘后","latestPrice":20.4734,"preClose":20.16,"latestTime":"17:57 EST","volume":4758,"amount":95955.23,"timestamp":1769209047622,"change":0.3134,"changeRate":0.015546,"amplitude":0.015546},"delay":0,"changeRate":0.05826771653543304,"floatShares":9741870,"shares":18716280,"eps":-3.878451,"marketStatus":"Market Closed","change":1.11,"latestTime":"01-23 16:00:00 EST","open":19.04,"high":20.66,"low":18.7781,"amount":5622908.935788001,"amplitude":0.098787,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.878451,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769418000000},"marketStatusCode":7,"adr":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":19.05,"preHourTrading":{"tag":"盘前","latestPrice":19.57,"preClose":19.05,"latestTime":"09:15 EST","volume":6,"amount":116.900004,"timestamp":1769177745745,"change":0.52,"changeRate":0.027297,"amplitude":0.027297},"postHourTrading":{"tag":"盘后","latestPrice":20.4734,"preClose":20.16,"latestTime":"17:57 EST","volume":4758,"amount":95955.23,"timestamp":1769209047622,"change":0.3134,"changeRate":0.015546,"amplitude":0.015546},"volumeRatio":1.245779607721969,"impliedVol":1.5492,"impliedVolPercentile":0.8643},"requestUrl":"/m/hq/s/TECX/tweets","defaultTab":"tweets","newsList":[{"id":"2602391441","title":"Tectonic Therapeutic Is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2602391441","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602391441?lang=en_us&edition=fundamental","pubTime":"2026-01-09 01:34","pubTimestamp":1767893640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TECX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 12:34 ET (17:34 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TECX"],"gpt_icon":0},{"id":"2588272082","title":"Tectonic Therapeutic to Participate in Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2588272082","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588272082?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:00","pubTimestamp":1764594025,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic Inc. will participate in two upcoming investor conferences in December 2025. The company will hold a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 3:30 PM EST in New York, NY, with President and CEO Alise Reicin, MD, as the presenter. Additionally, Tectonic will attend the Evercore 8th Annual Healthcare Conference for investor meetings on December 3, 2025, in Miami, FL. A live webcast of the fireside chat will be available on the company's website, with a replay accessible for approximately 90 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDLbRc74H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4127","LU2210149790.SGD","BK4585","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","EVR","BK4112","NDAQ","PIPR","LU2095319765.USD","IE00BGHQF748.EUR","TECX"],"gpt_icon":0},{"id":"2584186340","title":"Mizuho Securities Reaffirms Their Buy Rating on Tectonic Therapeutic (TECX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584186340","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584186340?lang=en_us&edition=fundamental","pubTime":"2025-11-20 15:55","pubTimestamp":1763625324,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Uy Ear reiterated a Buy rating on Tectonic Therapeutic yesterday. The company’s shares closed yesterday at $18.76. Ear co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-reaffirms-their-buy-rating-on-tectonic-therapeutic-tecx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-reaffirms-their-buy-rating-on-tectonic-therapeutic-tecx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","TECX"],"gpt_icon":0},{"id":"2581046163","title":"Tectonic Therapeutic Q3 EPS $(1.02) Beats $(1.05) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581046163","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581046163?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:07","pubTimestamp":1762466871,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.02) per share which beat the analyst consensus estimate of $(1.05) by 2.86 percent. This is a 15 percent increase over losses of $(1.20) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48706610/tectonic-therapeutic-q3-eps-1-02-beats-1-05-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TQQQ","USJW.SI","NQmain","QID","SQQQ","PSQ","MNQmain","BK4139","TSYW.SI","NVIW.SI","USAW.SI",".IXIC","TECX","QLD"],"gpt_icon":0},{"id":"2581012218","title":"Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2581012218","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581012218?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:01","pubTimestamp":1762462864,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA49XNCM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TECX"],"gpt_icon":0},{"id":"2579149718","title":"Tectonic Therapeutic Shares Rise in Premarket on Positive Data for XT45 Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2579149718","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579149718?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:25","pubTimestamp":1761827100,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic shares jumped in premarket trading Thursday after the company reported positive trial data for its treatment of pulmonary hypertension and heart failure.Shares traded 23% higher ahead of the opening bell at $22.90.Data from the phase 1b part B acute hemodynamic clinical trial showed that a single intravenous dose of its TX45 drug was well tolerated and brought on meaningful improvements in both left heart function and pulmonary hemodynamics.TX45 is Tectonic's new drug that aims to improve heart and lung function in patients with group 2 pulmonary hypertension and heart failure. This condition involves elevated blood pressure in the lungs due to left heart disease, leading to poor heart and lung performance.Tectonic also noted that there were no serious health issues and the drug was well tolerated among the cohort of patients.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tectonic Therapeutic Shares Rise in Premarket on Positive Data for XT45 Drug","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TECX"],"gpt_icon":0},{"id":"2579151723","title":"Mizuho Securities Keeps Their Buy Rating on Tectonic Therapeutic (TECX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2579151723","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579151723?lang=en_us&edition=fundamental","pubTime":"2025-10-30 08:55","pubTimestamp":1761785735,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Uy Ear from Mizuho Securities reiterated a Buy rating on Tectonic Therapeutic, with a price target of $85.00. The c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-their-buy-rating-on-tectonic-therapeutic-tecx-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-their-buy-rating-on-tectonic-therapeutic-tecx-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TECX","MFG"],"gpt_icon":0},{"id":"2579138473","title":"Tectonic Therapeutic Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2579138473","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579138473?lang=en_us&edition=fundamental","pubTime":"2025-10-30 04:01","pubTimestamp":1761768078,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic Inc. announced positive topline results from its Phase 1b Part B clinical trial evaluating TX45, a long-acting Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension in heart failure with reduced ejection fraction . The trial demonstrated that a single intravenous dose of TX45 was well tolerated and showed meaningful improvements in left heart function and pulmonary hemodynamics. No serious or severe adverse events, clinically significant changes in blood pressure, or immune-related reactions were reported. The company is also conducting the APEX Phase 2 trial of TX45 in patients with Group 2 pulmonary hypertension in heart failure with preserved ejection fraction , with topline results expected in 2026. The Phase 1b results were presented by the company on October 29, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL9GFJbv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TECX","IE00BKPKM429.USD","BK4139","LU2210150020.SGD","BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","BK4585","IE00BGHQF748.EUR","BK4588","IE00B64PRP62.GBP","LU0314104364.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2579139629","title":"Tectonic Therapeutic Inc - Tx45 Well Tolerated With No Serious Adverse Events in Ph-Hfref","url":"https://stock-news.laohu8.com/highlight/detail?id=2579139629","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579139629?lang=en_us&edition=fundamental","pubTime":"2025-10-30 04:01","pubTimestamp":1761768061,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUA9F1MB7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TECX","BK4139"],"gpt_icon":0},{"id":"2579139151","title":"Tectonic Therapeutic Inc - Tx45 Improves Heart Function and Pulmonary Hemodynamics in Ph-Hfref","url":"https://stock-news.laohu8.com/highlight/detail?id=2579139151","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579139151?lang=en_us&edition=fundamental","pubTime":"2025-10-30 04:01","pubTimestamp":1761768061,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUA9F1MB7:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TECX"],"gpt_icon":0},{"id":"2579138484","title":"Tectonic Therapeutic Announces Positive Topline Data From Phase 1B Part B Clinical Trial for Tx45 in Patients With Group 2 Pulmonary Hypertension in Hfref","url":"https://stock-news.laohu8.com/highlight/detail?id=2579138484","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579138484?lang=en_us&edition=fundamental","pubTime":"2025-10-30 04:01","pubTimestamp":1761768061,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUA9F1MB7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TECX","BK4139"],"gpt_icon":0},{"id":"2577235785","title":"Mizuho Securities Sticks to Their Buy Rating for Tectonic Therapeutic (TECX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2577235785","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577235785?lang=en_us&edition=fundamental","pubTime":"2025-10-22 17:35","pubTimestamp":1761125708,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Uy Ear reiterated a Buy rating on Tectonic Therapeutic today and set a price target of $85.00. The company’s shares close...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-tectonic-therapeutic-tecx-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-tectonic-therapeutic-tecx-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","TECX"],"gpt_icon":0},{"id":"2575231065","title":"Mizuho Securities Keeps Their Buy Rating on Tectonic Therapeutic (TECX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2575231065","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575231065?lang=en_us&edition=fundamental","pubTime":"2025-10-14 07:55","pubTimestamp":1760399706,"startTime":"0","endTime":"0","summary":"In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Tectonic Therapeutic, with a price target of $85.00. The compa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-their-buy-rating-on-tectonic-therapeutic-tecx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-their-buy-rating-on-tectonic-therapeutic-tecx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","TECX"],"gpt_icon":0},{"id":"2564393491","title":"Tectonic Therapeutic Shares up 4.4% Premarket After Oppenheimer Initiates Coverage With Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2564393491","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564393491?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:21","pubTimestamp":1756902117,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nL4N3UQ0TA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TECX"],"gpt_icon":0},{"id":"2564362622","title":"Oppenheimer Initiates Tectonic Therapeutic at Outperform With $80 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2564362622","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564362622?lang=en_us&edition=fundamental","pubTime":"2025-09-03 18:31","pubTimestamp":1756895471,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic (TECX) has an average rating of buy and mean price target of $79.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TECX","OPY"],"gpt_icon":0},{"id":"2564804869","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2564804869","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564804869?lang=en_us&edition=fundamental","pubTime":"2025-09-02 19:49","pubTimestamp":1756813765,"startTime":"0","endTime":"0","summary":"Globavend (GVH) shares fell 17% pre-bell Tuesday, shaving gains from the previous session.Professional Diversity Network (IPDN) stock was down 14%, paring Friday's rally.ALT5 Sigma (ALTS) shares were ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALTS","BK4007","BK4139","GVH","TECX","BK4130","BK4131","IPDN","BK4077"],"gpt_icon":0},{"id":"2562089037","title":"Tectonic Therapeutic Inc. to Participate in Upcoming September Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2562089037","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562089037?lang=en_us&edition=fundamental","pubTime":"2025-08-28 21:00","pubTimestamp":1756386027,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic, Inc., a clinical stage biotechnology company specializing in therapeutic proteins and antibodies targeting G-protein coupled receptors, is set to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025. Alise Reicin, MD, the President and CEO, will present at the fireside chat scheduled for 3:20 PM EDT.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via GlobeNewswire  on August 28, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL1tzTNY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106261372.USD","BK4139","LU2133065610.SGD","LU2210150020.SGD","LU1244550494.USD","LU2023251221.USD","LU0098860793.USD","LU2357305700.SGD","BK4581","LU1244550577.SGD","LU1989772840.SGD","LU2028103732.USD","IE00B64PRP62.GBP","LU0234570918.USD","LU2089284900.SGD","LU1363072403.SGD","LU1074936037.SGD","LU0158827781.USD","LU0795875169.SGD","BK4585","LU2210149790.SGD","LU0267386448.USD","LU0225283273.USD","BK4516","LU0006306889.USD","LU2095319765.USD","LU2271345857.HKD","NDAQ","BK4127","IE00BGHQF748.EUR","LU0314104364.USD","BK4588","LU1989772923.USD","IE00BZ1G4Q59.USD","TECX","LU0971096721.USD","LU1244550221.USD","LU0795875086.SGD","LU1720051017.SGD","LU1162221912.USD","LU1732800096.USD","BK4112","LU0106831901.USD","LU2347655156.SGD","LU0158827948.USD","IE00B3QW5Z07.USD","LU0912757837.SGD","LU2089283258.USD","LU1548497426.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2561489746","title":"TScan Therapeutics Appoints Leiden Dworak as Principal Accounting Officer, Jason Amello Continues as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2561489746","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561489746?lang=en_us&edition=fundamental","pubTime":"2025-08-21 04:11","pubTimestamp":1755720669,"startTime":"0","endTime":"0","summary":"TScan Therapeutics Inc. has announced a change in its management team. On August 14, 2025, Leiden Dworak was appointed as the company's Principal Accounting Officer. Dworak, who has been serving as Vice President of Finance since April 2022, replaces Jason A. Amello in this role. Amello will continue as the Chief Financial Officer and Principal Financial Officer. Dworak brings extensive experience from his previous roles at AVROBIO, Inc. and Moderna, Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 20, 2025,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250820:nNDL96cKKH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TCRX","BK4568","BK4548","BK4585","BK4501","BK4539","BK4532","BK4534","BK4588","TECX","BK4533","MRNA","BK4551"],"gpt_icon":0},{"id":"2558372644","title":"Tectonic Therapeutic Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2558372644","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558372644?lang=en_us&edition=fundamental","pubTime":"2025-08-12 20:00","pubTimestamp":1755000000,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic Inc reports results for the quarter ended June 30 - Earnings SummaryTectonic Therapeutic Inc TECX.OQ reported a quarterly adjusted loss of $1.07 per share for the quarter ended Ju","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nL8N3U40RC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TECX"],"gpt_icon":0},{"id":"2557828526","title":"Tectonic Therapeutic Inc  expected to post a loss of $1.03 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2557828526","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557828526?lang=en_us&edition=fundamental","pubTime":"2025-08-08 19:17","pubTimestamp":1754651825,"startTime":"0","endTime":"0","summary":"Tectonic Therapeutic Inc  expected to post a loss of $1.03 a share - Earnings Preview Tectonic Therapeutic Inc TECX.OQ TECX.O is expected to  show no change in quarterly revenue when it reports  resul","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U01PI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TECX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tectonictx.com","stockEarnings":[{"period":"1week","weight":0.0723},{"period":"1month","weight":-0.0752},{"period":"3month","weight":0.1755},{"period":"6month","weight":-0.0968},{"period":"1year","weight":-0.5223},{"period":"ytd","weight":-0.0336}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.0177},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.0107}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.037465},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.030507},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.05919},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.084898},{"month":5,"riseRate":0.714286,"avgChangeRate":0.074772},{"month":6,"riseRate":0.142857,"avgChangeRate":-0.048352},{"month":7,"riseRate":0.625,"avgChangeRate":0.131313},{"month":8,"riseRate":0.625,"avgChangeRate":0.020588},{"month":9,"riseRate":0.375,"avgChangeRate":-0.036701},{"month":10,"riseRate":0.875,"avgChangeRate":0.040067},{"month":11,"riseRate":0.5,"avgChangeRate":0.024692},{"month":12,"riseRate":0.5,"avgChangeRate":-0.049184}],"exchange":"NASDAQ","name":"Tectonic Therapeutic, Inc.","nameEN":"Tectonic Therapeutic, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tectonic Therapeutic, Inc.(TECX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tectonic Therapeutic, Inc.(TECX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tectonic Therapeutic, Inc.,TECX,Tectonic Therapeutic, Inc.股票,Tectonic Therapeutic, Inc.股票老虎,Tectonic Therapeutic, Inc.股票老虎国际,Tectonic Therapeutic, Inc.行情,Tectonic Therapeutic, Inc.股票行情,Tectonic Therapeutic, Inc.股价,Tectonic Therapeutic, Inc.股市,Tectonic Therapeutic, Inc.股票价格,Tectonic Therapeutic, Inc.股票交易,Tectonic Therapeutic, Inc.股票购买,Tectonic Therapeutic, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tectonic Therapeutic, Inc.(TECX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tectonic Therapeutic, Inc.(TECX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}